| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
Pronase E targets proteins, specifically the peptide bonds that link amino acids. As a mixture of proteases, it has a wide substrate specificity and can hydrolyze a broad range of peptide bonds. This makes it ideal for extensive protein digestion and the removal of protein contaminants from nucleic acid preparations.
|
|---|---|
| ln Vitro |
The quantity of most stimuli examined (PE vs. C) is greatly increased by protease E, particularly Ile, His, and Thr[1].
In vitro, Pronase E is characterized by its broad proteolytic activity. It is used to digest proteins into individual amino acids. Its activity is measured by its ability to hydrolyze a protein substrate, such as casein or hemoglobin. One unit of activity is typically defined as the amount of enzyme that releases 1 μmol of tyrosine per minute under specific conditions. |
| ln Vivo |
In vivo, Pronase E is not used as a therapeutic agent. It is a research reagent used in various laboratory applications. Its primary applications are in the preparation of samples for biochemical analysis, such as the isolation of DNA, RNA, and proteins.
|
| Enzyme Assay |
The in vitro enzyme activity assay for Pronase E involves incubating the enzyme with a protein substrate, such as casein, in a suitable buffer at an optimal pH and temperature. The reaction is stopped, and the amount of undigested protein or released amino acids is measured using a colorimetric method, such as the Folin-Ciocalteu assay. One unit of activity is defined as the amount of enzyme that releases 1 μmol of tyrosine per minute under the assay conditions.
|
| Cell Assay |
Pronase E is not typically used in cell culture studies for its biological effects. However, it is used in tissue dissociation protocols to isolate living cells from tissues. It can also be used to remove proteins from cell lysates. Its effects on cells are primarily related to its proteolytic activity, which can be controlled by using it at specific concentrations and for limited times.
|
| Animal Protocol |
In vivo animal experiments for Pronase E are not common. However, it may be used in some research applications, such as in the preparation of tissue sections for immunostaining. Its use is typically limited to in vitro applications.
|
| ADME/Pharmacokinetics |
Pronase E is a mixture of proteolytic enzymes that is stable in the pH range 5.0 to 9.0. It is typically supplied as an off-white to light yellow solid powder. It is soluble in water and aqueous buffers. It is typically stored at 4°C for short-term stability and at -20°C for long-term stability. Its activity is optimal at pH 9-10 for alkaline components.
|
| Toxicity/Toxicokinetics |
Toxicological data for Pronase E indicate that it can be a skin and respiratory sensitizer. Inhalation of the enzyme dust may cause allergic reactions in susceptible individuals. It is not intended for human therapeutic use. Standard safety precautions, including the use of personal protective equipment, should be followed.
|
| References | |
| Additional Infomation |
Pronase E is a research reagent with no clinical approval. It is a valuable tool for protein digestion, tissue dissociation, and the removal of protein contaminants from nucleic acid preparations. It is widely used in molecular biology, biochemistry, and cell biology laboratories for sample preparation.
|
| Exact Mass |
420.251
|
|---|---|
| CAS # |
9036-06-0
|
| Related CAS # |
Pronase E (Activity ≥ 4000 U/mg);9036-06-0
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
493.1±40.0 °C at 760 mmHg
|
| Flash Point |
209.6±27.4 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.518
|
| LogP |
4.99
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL
H2O : ~10 mg/mL |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
